Abstracts tagged "SLE"

Abstract Number: 1625 • 2017 ACR/ARHP Annual Meeting
Incidence and Outcomes of Venous Thromboembolism in Hospitalized Patients with Systemic Lupus Erythematosus: Results from Nationwide Inpatient Sample Database 2003-2011
Shweta Kishore¹, Varun Mittal², Shradha Ahuja³ and Vikas Majithia^1,4, ¹Division of Rheumatology, University of Mississippi, Jackson, MS, ²Division of Hematology and Oncology, Albert Einstein Healthcare Network, Philadelphia, PA, ³Division of Hospital Medicine, University of Mississippi, Jackson, MS, ⁴Jackson VA Medical Center and University of Mississippi, Jackson, MS
Background/Purpose: Venous thromboembolism (VTE) is a major cause of mortality and morbidity in hospitalized patients. Hospitalized patients with autoimmune disorders are particularly at risk of…
Abstract Number: 1917 • 2017 ACR/ARHP Annual Meeting
A Novel Type I Interferon Biomarker on B Cell Predicts with Disease Activity in SLE and Can be Measured By Cell Surface Tetherin (CD317)
Yasser M El-Sherbiny^1,2,3, Md Yuzaiful Md Yusof¹, Antonios Psarras¹, Elizabeth M.A. Hensor¹, Kumba Kabba¹, Alaa Mohamed^1,4, Miriam Wittmann⁵, Paul Emery^5,6 and Edward M Vital^1,5,7, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals, NHS Trust, Leeds, United Kingdom, ³Clinical Pathology dept., School of Medicine, Mansoura University, Mansoura, Egypt, ⁴Faculty of Medicine, Assiut University, Department of Rheumatology and Rehabilitation, Assiut, Egypt, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: SLE is an IFN-I-mediated disease with dysregulated handling of self-nuclear antigens triggering anti-viral immune mechanisms. The level of IFN-I activity appears to stratify for…
Abstract Number: 2633 • 2017 ACR/ARHP Annual Meeting
Patients with Secondary Sjögren’s Syndrome to SLE Are Characterized By Typical Autoantibodies and a Pro-Inflammatory State
Marika Kvarnstrom¹, Guillermo Ruacho², Johanna Gustafsson³, Agneta Zickert⁴, Vilija Oke⁵, Johan Rönnelid⁶, Kerstin Elvin⁷, Iva Gunnarsson⁸ and Elisabet Svenungsson⁸, ¹Unit of Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ²Department of Medicine, Unit of Rheumatology,, Stockholm, Sweden, ³Dep. of Medicine, Karolinska Institutet, Karolinska University Hospital, Unit of rheumatology,, Stockholm, Sweden, ⁴Department of Medicine, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁵Department of Medicine, Rheumatology Unit, Department of Medicine Solna, Rheumatology Unit, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, ⁶Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden, ⁷Department of Clinical Immunology and Transfusion Medicine,, 4Unit of Clinical Immunology, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose :Sjögren´s syndrome occurs in isolation (primary Sjögren´s syndrome, pSS), but it is also often secondary (sSS) to, and sometimes difficult to delineate from, other…
Abstract Number: 829 • 2017 ACR/ARHP Annual Meeting
Unraveling Race and Social Context in Understanding Disparities in Lupus Mortality in the United States
Titilola Falasinnu¹, Yashaar Chaichian², Latha Palaniappan³ and Julia F Simard⁴, ¹Health Research and Policy, Stanford University, Stanford, CA, ²Medicine, Immunology & Rheumatology Division, Stanford School of Medicine, Stanford, CA, ³Stanford University Medical Center, General Medical Disciplines, Stanford, CA, ⁴Division of Epidemiology, Health Research and Policy Department, Stanford School of Medicine, Stanford, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that is a source of significantly decreased life expectancy in the United States. Women and…
Abstract Number: 1628 • 2017 ACR/ARHP Annual Meeting
Atrial Fibrillation/Flutter Hospitalizations Among Patients with SLE and Diabetes Compared to the General U.S. Medicaid Population
Sarah Chen¹, Medha Barbhaiya², Michael A. Fischer³, Hongshu Guan⁴, Candace H. Feldman⁵, Brendan M. Everett⁶ and Karen H. Costenbader⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham & Women's Hospital, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁷Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: SLE patients have increased cardiovascular disease (CVD) risk, including higher risk of stroke, compared to age- and sex-matched diabetes mellitus (DM) patients. Although DM…
Abstract Number: 1919 • 2017 ACR/ARHP Annual Meeting
The SLE-Key Test Detects an SLE Serologic Signature That Persists over Time and Is Independent of Disease Activity
Chaim Putterman¹, Michelle Petri², Roberto Caricchio³, Jim C. Oates⁴, Pennina Safer⁵, Keren Jakobi-Brook⁵, Rachel Sorek⁵, Ilana Gluzman⁵, Steve Wallace⁶ and Irun R. Cohen^5,7, ¹Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY, USA, Bronx, NY, ²Medicine (Rheumatology), Division of Rheumatology, Johns Hopkins University School of Medicine, MD, USA, Baltimore, MD, ³Temple Lupus Clinic, Temple University, Philadelphia, PA, USA, Philadelphia, PA, ⁴Division of Rheumatology & Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ⁵ImmunArray Ltd., Rehovot, Israel, Rehovot, Israel, ⁶ImmunArray Inc., VA, USA, Richmond, VA, ⁷Weizmann Institute of Science, Rehovot, Israel, Rehovot, Israel
Background/Purpose: We have developed the iCHIP1,2 to profile repertoires of serum autoantibodies. The first iCHIP application was the SLE-key RuleOut test3,4 , to rule out…
Abstract Number: 2637 • 2017 ACR/ARHP Annual Meeting
A Novel Regulatory Antigen Presenting B Cell and Memory Regulatory T Cell Subsets Are Enriched during the Quiescent Phase of Childhood Onset Systemic Lupus Erythematosus
Joo Guan Yeo^1,2, Thaschawee Arkachaisri^1,3, Lena Das¹, Justin Hung Tiong Tan¹, Jing Yao Leong², Yun June Angela Tan⁴, Liyun Lai⁵, Loshinidevi D/O Thana Bathi², Phyllis Chen², Seck Choon Elene Lee¹, Yun Xin Book¹ and Salvatore Albani^5,6, ¹Rheumatology and Immunology Service, KK Women's and Children's Hospital, Singapore, Singapore, ²Singhealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ³Duke-NUS Medical School, Singapore, Singapore, ⁴Department of Paediatric Anaesthesia, KK Women's and Children's Hospital, Singapore, Singapore, ⁵SingHealth Translational Immunology and Inflammation Centre (STIIC), Duke-NUS Medical School, Singapore, Singapore, ⁶KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multi-factorial disease and the conventional oligo-dimensional investigative approach involving one or a few cell subsets at a time…
Abstract Number: 833 • 2017 ACR/ARHP Annual Meeting
Chronic Cutaneous Lupus Erythematosus Patients Have a Breakdown in Autoreactive VH4.34 Antibody Tolerance While Maintaining Tolerance to dsDNA and Chromatin
Scott Jenks¹, Regina Bugrovsky¹, Xiaoqian Wang^1,2, Aisha Hill³, Chungwen Wei⁴, S. Sam Lim⁵, Ignacio Sanz⁶ and Cristina Drenkard⁵, ¹Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA, ²Division of Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine, Atlanta, GA, ³Medicine, Emory University School of Medicine, atlanta, GA, ⁴Medicine, Emory University School of Medicine, Atlanta, GA, ⁵Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ⁶Rheumatology and Lowance Center for Human Immunology, Emory University School of Medicine and Lowance Center for Human Immunology, Atlanta, GA
Background/Purpose: While the contribution of humoral immunity to SLE is well established, the role it plays in chronic cutaneous lupus erythematosus (CCLE) is less clear.…
Abstract Number: 1633 • 2017 ACR/ARHP Annual Meeting
Use of Emergency Department (ED) and Resulting Hospitalization By Patients with Systemic Lupus Erythematosus (SLE) in a Predominantly Afro-Caribbean Inner-City Cohort
Maushmi Savjani¹, Justin Levinson² and Ellen M. Ginzler³, ¹Internal Medicine, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ²Medicine, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY, ³Rheumatology, Division of Rheumatology, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY
Background/Purpose: Given the complexity, chronicity and associated co-morbidities, management of SLE poses a challenge. Despite established care in private and fellow/resident clinics, our patients often…
Abstract Number: 2559 • 2017 ACR/ARHP Annual Meeting
KZR-616, a Selective Inhibitor of the Immunoproteasome, Blocks the Disease Progression in Multiple Models of Systemic Lupus Erythematosus (SLE)
Tony Muchamuel¹, Janet Anderl², R Andrea Fan², Henry W. B. Johnson³, Christopher J Kirk⁴ and Eric Lowe², ¹Pharmacology and Toxicology, Kezar Life Sciences, South San Francisco, CA, ²Biology, Kezar Life Sciences, South San Francisco, CA, ³Medicinal Chemistry, Kezar Life Sciences, South San Francisco, CA, ⁴Kezar Life Sciences, South San Francisco, CA
Background/Purpose: The proteasome inhibitor bortezomib has been used successfully to treat patients with SLE. The immunoproteasome is a distinct class of proteasome found predominantly in…
Abstract Number: 2638 • 2017 ACR/ARHP Annual Meeting
Inducible cAMP Early Repressor Promotes Glycolysis By Inhibiting the Pyruvate Dehydrogenase Phosphatase Catalytic Subunit 2 in Th17 Cells
Michihito Kono, Nobuya Yoshida, Nicole E. Skinner and George C. Tsokos, Beth Israel Deaconess Medical Center, Boston, MA
Background/Purpose: Th17 cells are key players in SLE. Because Th17 cells use mainly glycolysis, blocking glycolysis can inhibit Th17 cell differentiation and treatment of lupus-prone…
Abstract Number: 930 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Modified-Release Prednisone in Managing Moderate Activity SLE during Pregnancy: An Implemented Case-Control Study
Marianna Meroni¹, Véronique Laure Ramoni², Massimiliano Parodi³, Paolo Stobbione³ and Maurizio Cutolo⁴, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genova, Italy, ²Division of Rheumatology, IRCCS San Matteo Hospital Foundation, University of Pavia, Pavia, Italy, Pavia, Italy, ³Rheumatology Unit, Internal Medicine Department, A.O. S.S. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy, Alessandria, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Systemic lupus erythematosus (SLE) can affect young women and pregnancy still represents a challenge. Prednisone is safely used, at low doses (<7.5 mg daily),…
Abstract Number: 1655 • 2017 ACR/ARHP Annual Meeting
Interferon b Blockade Rescues Human BM-MSC Osteoblastogenesis Defects in Systemic Lupus Erythematosus
Lin Gao¹, Jennifer H. Anolik² and R. John Looney³, ¹medicine- allergy, immunology and rheumatology, University of Rochester Medical Center, Rochester, NY, ²Medicine- Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, ³University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bone marrow mesenchymal stromal cells (BM-MSCs) are multipotent stem cells that can differentiate into chondrocytes, osteoblasts and adipocytes. SLE has been implicated as a…
Abstract Number: 2563 • 2017 ACR/ARHP Annual Meeting
SH3BP2 Gain-of-Function Mutation Ameliorates Lupus in B6.MRL-Faslpr Mice
Akiko Nagasu¹, Tomoyuki Mukai¹, Masanori Iseki², Hajime Nagasu³, Shunichi Fujita¹, Takafumi Mito¹, Shoko Kodama¹, Yumi Sasae⁴, Naoki Kashihara³, Katsuhiko Ishihara², Yasuyoshi Ueki⁵ and Yoshitaka Morita¹, ¹Department of Rheumatology, Kawasaki Medical School, Kurashiki, Okayama, Japan, ²Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Okayama, Japan, ³Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Okayama, Japan, ⁴Department of Rheumatology, Kawasaki Medical School, Kurashiki Okayama, Japan, ⁵Department of Oral and Craniofacial Sciences, School of Dentistry, University of Missouri-Kansas City, Missouri-Kansas City, MO
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of autoantibodies, leading to multiple organ dysfunction. SH3BP2 (Src homology domain 3…
Abstract Number: 2645 • 2017 ACR/ARHP Annual Meeting
The Internalization of DNA-Antibodies By Podocytes during Lupus Nephritis
Anja Römer-Hillmann¹, Elisabeth Jung², Annika Engbers¹, Marcel Reinhardt¹, Hedda Wardemann³, Thomas Pap⁴ and Annett Jacobi⁵, ¹Institute of Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ²Department of Internal Medicine D, Rheumatology, University Hospital Muenster, Muenster, Germany, ³Deutsches Krebsforschungszentrum, Heidelberg, Germany, ⁴Institute for Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany, ⁵Internal Medicine, Ruppiner Kliniken GmbH, Neuruppin, Germany
Background/Purpose: Podocytes are postmitotic visceral epithelial cells, located at the Bowmans capsule of the kidney building up the slit diaphragm with their foot processes to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].